Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross BCR-ABL Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.518

    BCR-ABL Kinase Inhibitors

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.518 alerts

    Get alerted when Policy 5.01.518 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs pharmacy-benefit coverage and prior authorization for selected BCR-ABL tyrosine kinase inhibitors used to treat Philadelphia chromosome-positive leukemias and other specified malignancies or hematologic disorders. Coverage is determined by drug-specific medical-necessity criteria, including diagnosis, age, prior therapy response or intolerance, combination therapy, quantity limits, and continued clinical response.

    Policy Summary
    PayerPremera Bluecross
    PolicyBCR-ABL Kinase Inhibitors
    Policy CodePolicy 5.01.518
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that drug-specific medical-necessity criteria are met and, for reauthorization, continued positive clinical response.
    SourceLink
    POLICY UPDATE CHANGES

    The policy revised criteria for imatinib, dasatinib, and nilotinib and added indications for bosutinib and ponatinib.

    The policy recognizes NCCN Category 1 and 2A indications as proven and Category 2B and 3 indications as unproven.

    The policy clarified first-line and second-line therapy roles for BCR-ABL inhibitors.

    The initial authorization period for other reviews changed from 3 months to 6 months.

    Brand nilotinib tartrate was assigned a limit of 120 tablets per 30 days.

    Coverage criteria were added for generic bosutinib.

    Bosulif coverage now requires a trial of generic bosutinib.

    Coverage criteria were added for Cavhanza (nilotinib) for adults with Philadelphia chromosome-positive chronic myeloid leukemia.

    References to non-formulary exception reviews were removed.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    15Products or formulations addressed
    6 monthsMaximum initial authorization
    12 monthsMaximum reauthorization
    120 tabletsNilotinib quantity limit
    3 monthsObjective-response timeframe
    2Newly covered options

    Drug-Specific Coverage Criteria

    Bosulif (bosutinib)

    Bosulif (bosutinib) may be considered medically necessary when ALL applicable requirements are met and one listed indication applies.

    Bosulif criteria

    • Indication

      • The individual is an adult with accelerated- or blast-phase Ph+ CML and has resistance or intolerance to prior generic imatinib.
      • The individual is aged 1 year or older, has newly diagnosed chronic-phase Ph+ CML, and is receiving Bosulif.
      • The individual is aged 1 year or older, has chronic-phase Ph+ CML, has resistance or intolerance to prior generic imatinib, and has resistance or intolerance to prior generic bosutinib.

    Generic bosutinib

    Generic bosutinib may be considered medically necessary when one listed indication is met.

    Generic bosutinib indications

    • The individual is an adult with accelerated- or blast-phase Ph+ CML and has resistance or intolerance to prior generic imatinib.
    • The individual is aged 1 year or older and has newly diagnosed chronic-phase Ph+ CML.
    • The individual is aged 1 year or older, has chronic-phase Ph+ CML, and has resistance or intolerance to prior generic imatinib.

    Cavhanza (nilotinib)

    Cavhanza (nilotinib) may be considered medically necessary when ALL requirements are met.

    Cavhanza criteria

    • The individual is aged 18 years or older.
    • The individual has chronic-, accelerated-, or blast-phase Ph+ CML.
    • The individual has resistance or intolerance to prior generic imatinib.
    • Nilotinib requirement

      • The individual has resistance or intolerance to prior generic nilotinib.
      • The individual has documented drug interactions with generic nilotinib, such as use of H2 antagonists or proton pump inhibitors.

    Danziten (nilotinib)

    Danziten (nilotinib) may be considered medically necessary when ALL requirements are met.

    Danziten criteria

    • The individual is aged 18 years or older.
    • The individual has chronic-, accelerated-, or blast-phase Ph+ CML.
    • The individual has resistance or intolerance to prior generic imatinib.
    • The individual has resistance or intolerance to prior generic nilotinib.
    • The requested quantity is limited to 120 tablets per 30 days.120 tablets per 30 days

    Generic dasatinib

    Generic dasatinib may be considered medically necessary when the required prior-therapy criterion and one listed indication are met.

    Generic dasatinib criteria

    • The individual has resistance or intolerance to prior generic imatinib.
    • Indication

      • The individual is a newly diagnosed adult with chronic-phase Ph+ CML.
      • The individual is an adult with chronic-, accelerated-, or blast-phase Ph+ CML.
      • The individual is an adult with Ph+ ALL.
      • The individual has GIST.

    Generic dasatinib for newly diagnosed Ph+ ALL

    Generic dasatinib may be considered medically necessary for newly diagnosed Ph+ ALL when ALL requirements are met.

    Generic dasatinib for Ph+ ALL

    • The individual is pediatric or adult and is newly diagnosed with Ph+ ALL.
    • Generic dasatinib is used in combination with chemotherapy.

    Gleevec, Imkeldi, and generic imatinib

    Gleevec, Imkeldi, and generic imatinib may be considered medically necessary when the applicable prior-therapy requirement and one listed indication are met.

    Imatinib indications

    • The individual has adult or pediatric Ph+ CML in chronic, accelerated, or blast phase.
    • The individual is pediatric with chronic-phase Ph+ CML recurring after stem cell transplant.
    • The individual has adult or pediatric Ph+ ALL and imatinib is used in combination with chemotherapy.
    • The individual is an adult with MDS/MPD associated with PDGFR gene rearrangements.
    • The individual is an adult with aggressive systemic mastocytosis without the D816V c-Kit mutation or with unknown c-Kit status.

    Iclusig (ponatinib)

    Iclusig (ponatinib) may be considered medically necessary when ALL requirements for one pathway are met.

    Iclusig pathways

    • The individual is aged 18 years or older, has chronic-, accelerated-, or blast-phase Ph+ CML or Ph+ ALL, has resistance or intolerance to prior generic imatinib, and has resistance or intolerance to an additional tyrosine kinase inhibitor such as bosutinib, dasatinib, or nilotinib.
    • The individual is aged 18 years or older and has T315I-positive chronic-, accelerated-, or blast-phase Ph+ CML, T315I-positive Ph+ ALL, or newly diagnosed Ph+ ALL treated in combination with chemotherapy.

    Brand nilotinib tartrate

    Brand nilotinib tartrate may be considered medically necessary when ALL requirements are met.

    Brand nilotinib tartrate criteria

    • The individual is aged 18 years or older.
    • The individual has chronic-, accelerated-, or blast-phase Ph+ CML.
    • The individual has resistance or intolerance to prior generic imatinib.
    • The individual has resistance or intolerance to prior generic nilotinib.
    • The requested quantity is limited to 120 tablets per 30 days.120 tablets per 30 days

    Generic nilotinib

    Generic nilotinib may be considered medically necessary when ALL requirements are met.

    Generic nilotinib criteria

    • The individual has resistance or intolerance to prior generic imatinib.
    • Indication

      • The individual is an adult with chronic-, accelerated-, or blast-phase Ph+ CML.
      • The individual is an adult with Ph+ ALL.
      • The individual is a pediatric individual aged 1 year or older with chronic-phase Ph+ CML.

    Phyrago (dasatinib)

    Phyrago (dasatinib) may be considered medically necessary when ALL requirements are met for one listed pathway.

    Phyrago criteria

    • The individual has resistance or intolerance to prior generic imatinib.
    • Dasatinib requirement

      • The individual has resistance or intolerance to prior generic dasatinib.
      • The individual has documented drug interactions with generic dasatinib, such as use of H2 antagonists or proton pump inhibitors.
    • Indication

      • The individual is pediatric, aged 1 year or older, with chronic-phase Ph+ CML.

    Phyrago for pediatric Ph+ ALL

    Phyrago may be considered medically necessary for pediatric Ph+ ALL when ALL requirements are met.

    • The individual is aged 1 year or older and is newly diagnosed with Ph+ ALL.
    • Dasatinib requirement

      • The individual has resistance or intolerance to prior generic dasatinib.
      • The individual has documented drug interactions with generic dasatinib, such as use of H2 antagonists or proton pump inhibitors.
    • Phyrago is used in combination with chemotherapy.

    Scemblix (asciminib)

    Scemblix (asciminib) may be considered medically necessary when ALL requirements are met.

    Scemblix criteria

    • The individual is aged 18 years or older.
    • The individual has chronic-phase Ph+ CML.
    • Disease status

      • The disease is newly diagnosed.
      • The individual was previously treated.
      • The disease is T315I-positive.

    Sprycel (dasatinib)

    Sprycel (dasatinib) may be considered medically necessary when the required prior therapies and one listed indication are met.

    Sprycel criteria

    • The individual has resistance or intolerance to prior generic imatinib.
    • The individual has resistance or intolerance to prior generic dasatinib.
    • Indication

      • The individual is a newly diagnosed adult with chronic-phase Ph+ CML.
      • The individual is an adult with chronic-, accelerated-, or blast-phase Ph+ CML.
      • The individual is an adult with Ph+ ALL.

    Sprycel for newly diagnosed Ph+ ALL

    Sprycel may be considered medically necessary for newly diagnosed Ph+ ALL when ALL requirements are met.

    Sprycel for Ph+ ALL

    • The individual is pediatric or adult and is newly diagnosed with Ph+ ALL.
    • Sprycel is used in combination with chemotherapy.
    • The individual has resistance or intolerance to prior generic dasatinib.

    Tasigna (nilotinib)

    Tasigna (nilotinib) may be considered medically necessary when ALL requirements are met.

    Tasigna criteria

    • The individual has resistance or intolerance to prior generic imatinib and generic nilotinib.
    • Indication

      • The individual is an adult with chronic-, accelerated-, or blast-phase Ph+ CML.
      • The individual is an adult with Ph+ ALL.
      • The individual is a pediatric individual aged 1 year or older with chronic-phase Ph+ CML.

    Investigational or unlisted uses

    All other uses of medications listed in this policy are considered investigational.

    Investigational uses

    • The requested use is not included in the applicable drug-specific medical-necessity criteria in this policy.

    Uses of medications listed in this policy that are not included in the applicable drug-specific coverage criteria are considered investigational. Listed medications remain subject to the product’s U.S. Food and Drug Administration dosage and administration prescribing information.

    This medical policy does not apply to Medicare Advantage. Coverage is subject to the applicable member benefit plan and its limits and conditions.

    Coding and Operational Parameters

    Codingmixed
    N/ACoding
    Objective response timeframe
    TimeframeThree months
    AssessmentObjective response to prior therapy
    Policy useNo objective response after three months is considered resistance when selecting an alternative therapy
    Nilotinib quantity limit
    Quantity limit120 tablets per 30 days
    ProductsSpecified nilotinib products
    Coverage conditionRequested quantity must remain within the stated limit

    Authorization and Provider Requirements

    Prior Authorization

    Pharmacy Benefit Prior Authorization Required

    Coverage is managed through the pharmacy benefit and requires prior authorization. The request must undergo a drug-specific medical-necessity review under the applicable criteria.

    Prior Authorization

    Authorization Duration

    Initial authorization may be approved for up to 6 months. Reauthorization may be approved for up to 12 months when the drug-specific coverage criteria remain satisfied and chart notes demonstrate a positive clinical response.

    Note

    Six-Month Initial Authorization

    For all other reviews involving drugs listed in this policy, the initial authorization period is up to 6 months rather than 3 months.

    Clinical Background

    BCR-ABL is an abnormal gene associated with a specific chromosome in chronic myelogenous leukemia. It produces a constitutively active tyrosine kinase protein that can promote uncontrolled cancer-cell growth, cell division, genomic instability, and blast crisis in chronic myeloid leukemia. BCR-ABL tyrosine kinase inhibitors target this abnormal protein and are used primarily for Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia, with selected uses in other tumors and hematologic disorders.

    Definitions

    Resistance
    DefinitionNo objective response to prior therapy after three months
    PurposeUsed to determine resistance when selecting an alternative therapy
    Therapies addressedImatinib and, for certain drugs, bosutinib, dasatinib, or nilotinib
    Resistance or intolerance
    PrerequisiteResistance or intolerance to prior therapy
    Applies toBranded products and later-line BCR-ABL inhibitors
    Documentation focusPrior treatment response, resistance, or intolerance must support the applicable coverage criteria

    Initial Therapy

    Initial therapy

    Initial coverage is available only when the applicable drug-specific criteria are satisfied.

    Initial authorization

    • The requested drug is one of the medications listed in this policy.
    • The individual has a policy-listed indication.
    • All applicable age, disease-phase, mutation, prior-therapy, resistance or intolerance, interaction, and combination-therapy requirements are met.
    • The requested quantity is within any stated limit.

    Reauthorization

    Reauthorization

    Reauthorization criteria apply to all drugs listed in the policy.

    Continuation criteria

    • The drug-specific coverage criteria continue to be met.
    • Chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    Step Therapy Requirements

    DrugApplicable pathwayRequired prior therapy
    Generic bosutinibAdults with accelerated- or blast-phase Ph+ CML with resistance or intolerance; or individuals aged 1 year or older with chronic-phase Ph+ CML who are newly diagnosed or have resistance or intolerance to generic imatinib.Resistance or intolerance to prior generic imatinib is required for the applicable resistant-disease pathways. Three months without an objective response is considered resistance.
    Bosulif (bosutinib)Adults with accelerated- or blast-phase Ph+ CML with resistance or intolerance; or individuals aged 1 year or older with chronic-phase Ph+ CML who are newly diagnosed or have resistance or intolerance to generic imatinib.For the chronic-phase resistant-disease pathway, resistance or intolerance to prior generic imatinib and prior generic bosutinib is required. Three months without an objective response is considered resistance.
    Drug or productApplicable disease pathwayRequired sequential therapy
    Brand nilotinib products: Cavhanza, Danziten, and brand nilotinib tartratePh+ CML; age and disease-phase requirements vary by product.Prior generic imatinib is required. Depending on the product, prior generic nilotinib is also required, or documented drug interactions with generic nilotinib may qualify. Quantity limits apply to specified products.
    Generic nilotinibAdult Ph+ CML, adult Ph+ ALL, or pediatric chronic-phase Ph+ CML age 1 year or older.Resistance or intolerance to prior generic imatinib is required.
    Phyrago (dasatinib)Ph+ CML or adult Ph+ ALL; pediatric chronic-phase Ph+ CML age 1 year or older.Resistance or intolerance to prior generic imatinib and generic dasatinib is required, or documented drug interactions with generic dasatinib may qualify.
    Scemblix (asciminib)Adults age 18 years or older with chronic-phase Ph+ CML that is newly diagnosed, previously treated, or T315I-positive.Resistance or intolerance to prior generic imatinib is required. For alternative prescribing, three months without an objective response to bosutinib, dasatinib, or nilotinib is considered resistance.
    Sprycel (dasatinib)Ph+ CML, Ph+ ALL, GIST, or pediatric chronic-phase Ph+ CML, as specified.Resistance or intolerance to prior generic imatinib and generic dasatinib is required.
    Tasigna (nilotinib)Adult Ph+ CML, adult Ph+ ALL, or pediatric chronic-phase Ph+ CML age 1 year or older.Resistance or intolerance to prior generic imatinib and generic nilotinib is required.
    Iclusig pathwayEligibilityRequired prior therapy
    Resistant or intolerant diseaseAdults age 18 years or older with chronic-, accelerated-, or blast-phase Ph+ CML or Ph+ ALL.Resistance or intolerance to prior generic imatinib and an additional tyrosine kinase inhibitor, such as bosutinib, dasatinib, or nilotinib, is required. Three months without an objective response to the applicable therapy is considered resistance.
    T315I-positive disease or newly diagnosed Ph+ ALLAdults age 18 years or older with T315I-positive chronic-, accelerated-, or blast-phase Ph+ CML; T315I-positive Ph+ ALL; or newly diagnosed Ph+ ALL treated in combination with chemotherapy.No prior-therapy step is specified for this pathway.
    StepRequired trialApplies before
    1A trial of generic bosutinib is required.Bosulif (bosutinib) coverage.

    Quantity Limits

    Cavhanza (nilotinib)
    ProductCavhanza (nilotinib)
    Limit120 tablets
    PeriodPer 30 days
    Danziten (nilotinib)
    ProductDanziten (nilotinib)
    Limit120 tablets
    PeriodPer 30 days

    Site of Care and Administration

    Note

    Oral prescription therapy

    The listed BCR-ABL kinase inhibitors are administered orally by prescription in the home setting.

    Policy Summary
    PayerPremera Bluecross
    PolicyBCR-ABL Kinase Inhibitors
    Policy CodePolicy 5.01.518
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that drug-specific medical-necessity criteria are met and, for reauthorization, continued positive clinical response.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaCoding and Operational ParametersAuthorization and Provider RequirementsClinical BackgroundDefinitionsInitial TherapyReauthorizationStep Therapy RequirementsQuantity LimitsSite of Care and Administration
  1. The requested quantity is limited to 120 tablets per 30 days.120 tablets per 30 days
  2. The individual is pediatric and has chronic-phase Ph+ CML.
  3. The individual is an adult with HES and/or CEL.
  4. The individual is an adult with unresectable, recurrent, and/or metastatic DFSP or aggressive desmoid tumors.
  5. The individual has recurrent chordoma, treated as single-agent therapy or in combination with cisplatin or sirolimus.
  6. The individual has PVNS/Tenosynovial Giant Cell Tumor treated with single-agent therapy.
  7. The individual has Kit (CD117)-positive GIST, melanoma, or other tumors.
  8. The individual has Ph+ NHL—lymphoblastic lymphoma.
  9. The individual is a newly diagnosed adult with chronic-phase Ph+ CML.
  10. The individual is an adult with chronic-, accelerated-, or blast-phase Ph+ CML.
  11. The individual is an adult with Ph+ ALL.
  12. The individual has resistance or intolerance to prior generic imatinib.
  13. The individual has GIST.
  14. The individual is pediatric with chronic-phase Ph+ CML.
  15. Step Therapy

    Generic-First and Sequential Therapy

    Apply the required generic-first and sequential-therapy rules before requesting coverage for a branded or subsequent tyrosine kinase inhibitor. Documentation must show resistance or intolerance to the required prior generic therapy; lack of an objective response after 3 months is considered resistance for purposes of prescribing an alternative therapy.

    • Required prior therapy may include generic imatinib and, depending on the requested drug, generic bosutinib, dasatinib, nilotinib, or another specified agent.
    • Document qualifying drug interactions when the criteria allow an interaction-based alternative to resistance or intolerance.
    Step Therapy

    Generic Bosutinib Trial Required Before Bosulif

    Before requesting Bosulif (bosutinib), document a trial of generic bosutinib and show resistance or intolerance to that therapy. Requests that do not establish the required generic bosutinib trial may not meet coverage criteria.

    Documentation Required

    Required Clinical Records

    Submit medical records supporting medical necessity for the requested drug and indication. Records should include office visit notes containing the diagnosis, relevant history, physical evaluation, and medication history.

    Documentation Required

    Continuation Documentation Required

    For reauthorization, submit current chart notes showing that the individual continues to meet the drug-specific coverage criteria and is demonstrating a positive clinical response to therapy. Without this continuation documentation, reauthorization may be denied.

    Documentation Required

    Category 2B Supporting Evidence

    A Category 2B off-label use may be considered only when supported by significant peer-reviewed Phase II or Phase III studies demonstrating treatment effectiveness.

    • NCCN Category 1 and 2A uses are recognized as medically accepted.
    • Category 2B uses are otherwise considered unproven and require the specified supporting evidence.
    Denial Risk

    Use Outside Listed Criteria

    Uses of the medications outside the indications and criteria listed in this policy are considered investigational and are not eligible for coverage under the listed medical-necessity criteria.

    Denial Risk

    Drug-Specific Criteria Not Met

    Coverage may be denied when the requested drug's drug-specific medical-necessity criteria are not met. Verify the indication, age and disease phase requirements, required prior-therapy sequence, resistance or intolerance, combination-therapy requirements, and any applicable quantity limit before submitting the request.

    Denial Risk

    Insufficient Continuation Evidence

    Reauthorization may be denied when submitted records do not demonstrate continued medical necessity and a positive clinical response to therapy. Include current chart notes and treatment-response documentation with each continuation request.

    Billing Rule

    Quantity Limit Exceeded

    Do not exceed the quantity limit for covered nilotinib products subject to this policy. Cavhanza, Danziten, and brand nilotinib tartrate requests are limited to 120 tablets per 30 days when that product's criteria apply.

    • Quantity limit: 120 tablets per 30 days.
    Denial Risk

    Insufficient Evidence for Off-Label Use

    Category 3 uses are considered unproven and do not support coverage. A Category 2B off-label use is also unsupported unless the provider submits significant peer-reviewed Phase II or Phase III studies demonstrating treatment effectiveness.

    • Do not rely on NCCN Category 3 evidence as support for coverage.
    • Category 2B evidence without the required peer-reviewed studies does not support the use.
    Philadelphia chromosome-positive (Ph+)
    AbbreviationPh+
    MeaningPhiladelphia chromosome-positive
    Disease indicationsChronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)
    Philadelphia chromosome
    Chromosomal changeTranslocation involving chromosome regions 9q34 and 22q11
    Gene fusionPart of the BCR gene fuses with part of the ABL gene
    ResultThe BCR-ABL fusion gene is located on the shortened chromosome 22
    BCR-ABL
    ProteinA tyrosine kinase fusion protein
    ActivityConstitutively active
    Clinical effectPromotes cell division and can contribute to genomic instability and blast crisis in CML
    Asciminib
    Drug classABL/BCR-ABL1 tyrosine kinase inhibitor
    Binding siteABL myristoyl pocket
    MechanismInhibits ABL1 kinase activity of the BCR-ABL1 fusion protein
    Brand nilotinib tartrate
    ProductBrand nilotinib tartrate
    Limit120 tablets
    PeriodPer 30 days
    Brand nilotinib tartrate
    ProductBrand nilotinib tartrate
    Updated limit120 tablets
    PeriodPer 30 days